TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced HNSCC who have initially progressed on pembrolizumab or pembrolizumab/platinum chemotherapy.
Phase:
PHASE1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute